Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase I / II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis


This is a multicenter, non-randomized, open-label, phase I / II study to evaluate the safety and tolerability of AMG 510 plus MVASI in subjects with advanced KRAS p.G12C mutant non-small cell lung cancer (NSCLC) with small, untreated brain metastases.
Iams, Wade

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: